Table 2 Frequency of the most common adverse events
| Â | Baseline | After treatment | ||||
|---|---|---|---|---|---|---|
Adverse Event | Grade 1–2 | Grade 3–4 | Total | Grade 1–2 | Grade 3–4 | Total |
Liver function | 97(20.5%) | 2(0.4%) | 99(20.9%) | 208 (43.9%) | 20 (4.2%) | 228 (48.1%) |
 ALT | 31(6.5%) | 1(0.2%) | 32(6.8%) | 181 (38.2%) | 14 (3.0%) | 195 (41.1%) |
 AST | 63(13.3%) | 0(0%) | 63(13.3%) | 144 (30.4%) | 13 (2.7%) | 157 (33.1%) |
 TBIL | 33(7%) | 1(0.2%) | 34(7.2%) | 17 (3.6%) | 3 (0.6%) | 20 (4.2%) |
Impaired renal function | ||||||
 eGFR | 6(1.3%) | 1(0.2%) | 7(1.5%) | 29 (6.1%) | 2 (0.4%) | 31 (6.5%) |
Dyslipidemia | 116(24.4%) | 7(1.5%) | 123(25.9%) | 328 (69.2%) | 48 (10.1%) | 376 (79.3%) |
 TC | 31(6.5%) | 0(0%) | 31(6.5%) | 253 (53.4%) | 8 (1.7%) | 261 (55.1%) |
 TG | 92(19.4%) | 3(0.6%) | 95(20%) | 265 (55.9%) | 38 (8.0%) | 303 (63.9%) |
 LDL-c | 24(5.1%) | 4(0.8%) | 28(5.9%) | 112 (23.6%) | 13 (2.7%) | 125 (26.4%) |
Skin lesions | ||||||
 Erythra | 34(7.2%) | 1(0.2%) | 35(7.4%) | 54 (11.4%) | 1 (0.2%) | 55 (11.6%) |
Nervous system | 328(69.2%) | 25(5.3%) | 353(74.5%) | 431 (90.9%) | 22 (4.6%) | 453 (95.6%) |
 Headache | 44(9.3%) | 0(0%) | 44(9.3%) | 51 (10.8%) | 0 (0%) | 51 (10.8%) |
 Insomnia | 321(67.7%) | 0(0%) | 321(67.7%) | 446 (94.1%) | 0 (0%) | 446 (94.1%) |
 Anxiety | 115(24.3%) | 19(4%) | 134(28.3%) | 192 (40.5%) | 14 (3.0%) | 206 (43.5%) |
 Depression | 92(19.4%) | 12(2.5%) | 104(21.9%) | 176 (37.1%) | 14 (3.0%) | 190 (40.1%) |
Total | 367(77.4%) | 36(7.6%) | 403(85.0%) | 387 (81.7%) | 85 (17.9%) | 472 (99.6%) |